# Shahneen Sandhu

Source: https://nuclide.cc/people/sandhu-shahneen/  
Nuclide record `sandhu-shahneen` (Person). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

Runs the medical oncology side of Peter Mac's theranostics programme, combining lutetium-PSMA with hormonal and immune therapies.

## Summary

Shahneen Sandhu is a medical oncologist and Lead for Genitourinary Oncology Theranostics at the Peter MacCallum Cancer Centre in Melbourne. She runs the medical oncology side of Peter Mac's theranostics programme, leading combination trials such as PRINCE and UpFrontPSMA that pair lutetium-177 PSMA-617 with androgen receptor pathway inhibitors, chemotherapy and immunotherapy. Her publications include the UpFrontPSMA trial of sequential lutetium-177 PSMA-617 and docetaxel against docetaxel alone in metastatic hormone-sensitive prostate cancer. She also contributes to melanoma and early-phase research.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Medical oncologist; Lead, Genitourinary Oncology Theranostics, Peter Mac
- Specialisms: Prostate cancer; Theranostics; Melanoma; Early-phase trials

## Sources

- Peter MacCallum Cancer Centre: https://www.petermac.org
- PubMed author search: https://pubmed.ncbi.nlm.nih.gov/?term=Sandhu%20S%5BAuthor%5D%20Peter%20MacCallum%20prostate%20PSMA

## Connected records

- isotopes: [Lutetium-177](https://nuclide.cc/isotopes/lu-177/)
- indications: [Prostate cancer](https://nuclide.cc/indications/prostate/)
- technologies: [Radioligand therapy (beta emitters)](https://nuclide.cc/technologies/radioligand-therapy/)
- targets: [PSMA](https://nuclide.cc/targets/psma/)
- drugs: [Lutetium-177 vipivotide tetraxetan](https://nuclide.cc/drugs/pluvicto/)
- institutions: [ANZUP Cancer Trials Group](https://nuclide.cc/institutions/anzup/), [Peter MacCallum Cancer Centre](https://nuclide.cc/institutions/peter-mac/)
- ideas: [Adding a checkpoint inhibitor to PSMA radioligand therapy](https://nuclide.cc/ideas/idea-rlt-plus-checkpoint-inhibitor/), [Adding a PARP inhibitor to PSMA radioligand therapy](https://nuclide.cc/ideas/idea-rlt-plus-parp-inhibitor/)
- pairings: [177Lu-PSMA-617 (Pluvicto) with olaparib](https://nuclide.cc/pairings/pluvicto-plus-olaparib/)
- key papers: [TheraP: [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer](https://nuclide.cc/key-papers/paper-therap-lancet-2021/)

---
JSON: https://nuclide.cc/api/v1/entities/sandhu-shahneen.json